The UK and US have forged a major bilateral deal that will guarantee zero duties on British medicine shipments entering the US market.
Agreement Details of the Pact
In exchange for the tariff guarantee, the UK has agreed to raise expenditure on medicines through the public health system. This move secures that duties on these crucial products will be held at zero for a period of three years.
This agreement is in response to recent warnings to significantly raise tariffs on branded pharmaceutical products, with potential rates floated reaching 100%.
"This agreement with the UK bolsters the worldwide climate for cutting-edge drugs and brings much-needed balance to American-British medicine commerce," a statement said.
Commercial Importance
Drugs constitute one of the UK's biggest exports to the United States, which is easily the biggest buyer for leading UK drugmakers.
Export figures indicate that in the one-year period prior to September, the UK shipped medicines valued at billions to the US. This figure represented 17.4% of all goods exports in that timeframe.
"This deal protects work, boosts investment and facilitates the UK to emerge as a international leader for biotech and pharma," a government official stated.
Key UK Commitments
The deal involves several notable pledges from the United Kingdom:
- Price Threshold Increase: The UK will lift the price threshold at which it deems new treatments to be prohibitively costly by a quarter.
- Higher Drug Budget: There is a target to double total public funding on medicines from 0.3% of GDP to 0.6% over the coming ten years.
- Refund Ceiling: The amount drug companies must refund to the NHS to prevent overspending will be restricted at fifteen percent. In the past, refunds topped 20%.
Industry Background
The pact follows a protracted row between the sector and the ministers over medicine costs and NHS adoption.
These tensions were intensified by claims that American customers were paying a premium for the equivalent treatments than people in the other developed nations.
In recent months, several large manufacturing plans in the UK have been paused or cancelled, while major funding commitments have been directed toward projects in the United States.
One official stated that the NHS had to increase expenditure on treatments, noting that its budget allocation on drugs had declined as a proportion of its resources over the past decade.
